My watch list
my.bionity.com  
Login  

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

GBI Research, the leading business intelligence provider, has released its latest research “Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market”, which provides insights into sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders R&D pipeline. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatments is also presented.

Report Highlights
GBI Research, the leading business intelligence provider has released its latest research “Sleep Disorders Market to 2017 – Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market”, which essentially provides insights on sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders treatments across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatment is also presented.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

High Growth Rate and Increasing Necessity for CNS Drugs has Made the Sleep Disorder Market Attractive

The sleep disorders market has been a fast growing market, with insomnia considered to be the prime factor for chronic disability in the workforce. In 2010, the Sleep Disorders Market was worth $3.5 billion, which is forecast to decrease to $3.4 billion by 2017, with a rate of -0.4% between 2010 and 2017. This is mainly affected by insomnia, which is a leading indication among all types of sleep disorders.

The insomnia therapeutics market has been growing at a fast pace over the past few years, but is expected to decline with a rate of -3.8% from 2011 to 2017 due to high competition in the market, which will be a barrier for prospective entrants. This competition can be transmitted over other indications in the market such as restless leg syndrome, narcolepsy and sleep apnea. This can be carried out by practicing patient awareness about the diseases and types of treatments, while the other method is by increasing diagnosis.

Sleep Disorders Market, Revenue Forecasts ($bn), 2002–2017

Source: GBI Research

The Insomnia Market will Decline Moderately Due to Patent Expirations

The insomnia therapeutics market was a growing market during 2002-2009, and the growth was dominated by the US market. The growth rate is likely to decline from 2011 onwards due to the impact of patent expiry of key drugs. However, new branded drugs will minimize the impact of generic erosion to some extent. This impact will be seen due to patent expiries in the insomnia market, as it accounts for approximately 79% share of the global market. The global insomnia therapeutics market is expected to decline at a CAGR of -3.8%, from $2.8 billion in 2010 to $2.1 billion in 2017. The major causes for decline in the market are patent expiries of major drugs and weak profile of current pipeline molecules. The global insomnia therapeutics market in 2010 was worth $2.8 billion, which was primarily formed of three brands, namely Lunesta (eszopiclone), Paxil (paroxetine) and Ambien (zolpidem). The cost of therapy for branded products is in the range of $750 to $1,002 for duration of six months, as compared to those of generics which is between $10 and $20 for the same duration. The most popular product for insomnia was Ambien (including generics and (Controlled Releases [CRs]), which demonstrates the large extent to which older generation products have been successful in terms of satisfying market demand. Ambien was approved for short term treatment of insomnia, while Ambien CR was approved for prescription for up to six months in 1991. The Average Selling Price (ASP) of products in the market is in the
Restless Leg Syndrome, Narcolepsy and Sleep Apnea are Dominated by Late-Stage Pipeline Molecules that will Boost the Competition

The restless leg syndrome, narcolepsy and sleep apnea pipeline portfolios have 12, five and 11 molecules across the different developmental stages, respectively. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 79% of the total number of pipeline programs. This indicates that the imminent launch of these drugs could increase the sleep disorder market value.

The restless leg syndrome market has a strong pipeline that will support the growth of this market, thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as UCB Group, GlaxoSmithKline plc, axxonis Pharma AG, Ligand Pharmaceuticals Incorporated, National Institute of Neurological Disorders and Stroke, Kyowa Hakko Kirin Co., Ltd., Jazz Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Omeros Corporation and Manhattan Pharmaceuticals, Inc., are actively developing molecules for restless leg syndrome.

The entry of pipeline molecules will boost the sleep disorder therapeutics market, thereby bringing about further rises in the sleep disorder therapeutics market in the coming years. Rapid entry of new players and highly active pipelines will intensify competition.

Sleep Disorder Therapeutics Market, R&D Pipeline by Phase (%), 2004-2010

Source: GBI Research’s Internal Database, Company Websites, Clinicaltrials.gov

Pharmacy / Drugs   Market study
Year:   2011
Price:   3,500.00€
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE